Skip to main content
. 2017 Mar 17;8(19):31415–31423. doi: 10.18632/oncotarget.16329

Figure 4. Gain-of-function system.

Figure 4

Cells were transfected with either empty vector “control” or the plasmid expressing the fusion “DUS4L-BCAP29”. Stable cells expressing the fusion were selected with corresponding antibiotics. (A) Overexpression of DUS4L-BCAP29 promoted cell proliferation in GES-1 and RWPE-1 cell lines. (B) Overexpression of DUS4L-BCAP29 promoted cell motility in GES-1 and RWPE-1 cell lines. Wound healing assays were conducted on stable cells as described before. *p < 0.05